Probio Invest
Healthcare, long/short equity

Osiris Therapeutics' Survival In Doubt After Losing 'Pass-Through' Status In 2015

Osiris (NASDAQ:OSIR) is a stem cell company focused on developing and marketing products in orthopedics, sports medicine and wound care. They currently market and distribute Grafix and Ovation for acute and chronic wounds, Cartiform, a viable cartilage mesh for cartilage repair, and OvationOS, a viable bone matrix for bone growth.

The company reported that product revenue during the first quarter of 2014 was $10.1 million. The gross margin was 78%. However, we believe that both the product revenue and profit margin will take a huge hit in 2015 due to the loss of "Pass-Through" status. According to the new proposal that will be published by the Centers for Medicare & Medicaid Services (CMS) on July 14th, 2014, Grafix...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details